shape therapeutics leadership team

Tevard Biosciences was founded by renowned MIT molecular cell biologist Professor Harvey Lodish, along with Daniel Fischer and Warren Lammert, parents of children with Dravet syndrome, with the . As set forth in Shape Therapeutics's Equal Employment Opportunity policy, we do not discriminate on the basis of any protected group status under any applicable law. SEATTLE, April 20, 2021 (GLOBE NEWSWIRE) -- Shape Therapeutics Inc. (ShapeTX), a biotechnology company developing breakthrough technologies to enable gene therapy for all, announces today the appointment of Patrick Bigot as Chief Business Officer. Shape Life! free lookups / month. shapetx.com, Business and Media Contact:Shape Therapeutics Inc.Cindy Fung, Ph.D. cindy@shapetx.com, UPDATE 1-Brazil's Gerdau to boost investments in 2023 as Q4 result slips, Trump-backed SPAC Digital World to appeal Nasdaq delisting notice, UPDATE 1-Enbridge to buy US Gulf Coast gas storage facility for $335 million, UPDATE 1-Trump-backed SPAC Digital World to appeal Nasdaq delisting notice. Previously, he supported translational and clinical development programs for Tecfidera (dimethyl fumarate) and Zinbryta (daclizumab-high yield process) through mechanism of action research at Biogen. from Harvard Law School. Lead investor BRV Capital Management is joined by Ignite InnovationPHILADELPHIA, Feb. 28, 2023 /PRNewswire/ -- Verismo Therapeutics, a clinical-st. Prior to Genentech, Mr. Bigot was Director of Business Development at Chiron. Get contact details including emails and phone numbers Most recently, he served as Global Head, Strategic Alliances at Verily, a subsidiary of Alphabet. So far, I like the team. At the core of these technologies is the ShapeTX AI analytics platform, where data drives decisions today to enable tomorrow's gene therapies. Get the full list, Youre viewing 5 of 10 investors. As Doug noted, our full year net product revenue was $843.8 million . Shape Therapeutics, Inc. Shape Life! Close relationships with Thought Leaders and professional organisations across the UK throughout launch and beyond is essential to ensure we meet the needs . Mr. Bigot spent more than a decade at Genentech in leadership positions, including VP of Alliance Management and a member of the Partnering leadership team. SEATTLE, July 15, 2021 (GLOBE NEWSWIRE) -- Shape Therapeutics Inc. (Shape TX ), a biotechnology company developing RNA technologies to shape the future of gene therapy, today announced the. The ShapeTX platform enables pharma innovators to design treatments across a wide range of diseases, including rare genetic disorders as well as debilitating conditions, such as Alzheimer's,. Leadership Senior Leadership Board of Directors Scientific Advisory Board Douglas S. Ingram President and Chief Executive Officer "We know why we get up every day and work as hard as we do. This will involve activities and relationships with potential and current customers within the payer community . resistance to cancer treatment. Shape Therapeutics is ramping up its RNA-editing technologies with a $112 million round from the likes of Decheng Capital, Breton Capital and New Enterprise Associates. Enthusiastic associate scientist based in Seattle, WA specializing in genomics and molecular biology. Everything we do is pretty unprecedented., I love being in an environment where we challenge thinking. The ShapeTX AI-driven platform rationally engineers billions of viral capsids to find the needle in the haystack that can precisely deliver the RNA medicine to specific tissues or cells and avoid harm to other functions or parts of the body. Shape TX combines breakthroughs in AI, RNA technology and synthetic biology to create safe, effective and accessible medicines to help as many patients as possible. ", Im here to bring genetic medicine to life. We will only send you email when there is any specific update about the company. {{ userNotificationState.getAlertCount('bell') }}. focus on diversity and equityRead More. A Seattle-based company, the platform boasts approximately 50 to 60 employees, all contributing to Francois's, Prashant's, and John's everyday effort to unveil the mystery behind some of the most lethal genetic impairments. Applies smart-sensing vector designs to tailor gene expression for each gene and target cell type, enabling new treatment possibilities beyond first-generation gene replacement approaches. Contact During his tenure, he led the creation and management of partnerships for multiple assets that were growth drivers for Genentech. Copyright 2023 CB Information Services, Inc. All rights reserved. 2 min read SEATTLE, April 20, 2021 (GLOBE NEWSWIRE) -- Shape Therapeutics Inc. (Shape TX ), a biotechnology company developing breakthrough technologies to enable. Through diversity of thought, scientific knowledge, professional rigor and focus we are merging cutting-edge science with extensive drug development expertise to unlock cures to many debilitating diseases. Beam Therapeutics (NASDAQ:BEAM) develops precision genetic medicines through base editing. Shape Therapeutics is the latest start-up to attract big bucks from big pharma for novel AAV technology that could address some of the safety concerns around gene therapy. Lorem ipsum dolor sit amet consectetur adipisicing elit. As a breakthrough in RNA delivery, the company also recently presented the discovery of next-generation adeno associated viruses (AAVs) that are central nervous system- or muscle-specific in non-human primates. Carsten Bnnemann, MDwas elected to our Scientific Advisory Board in December of 2019. Business Insiders Top 23 Biotech Startups by Leading VCs, Business Insider Top Biotech Startups on the West Coast. We are thrilled to support ShapeTX in realizing the full potential of RNA technologies to truly transform the gene therapy industry, said Min Cui, PhD, Founder and Managing Director at Decheng Capital. ShapeTX is committed to data-driven scientific advancement, passionate people and a mission of providing life-long cures to patients. You can read more about your cookie choices at our privacy policyhere. No credit card required. . We [] Shape Therapeutics's Vice President, Head of Research is David Huss. Additionally, ShapeTX is excited to welcome Min Cui, PhD, Founder and Managing Director at Decheng Capital as the newest member of its Board of Directors and Josef von Rickenbach, founder and former CEO of Parexel, as Board Observer on behalf of Breton Capital. Ms. Taylor Ash began her career as an attorney at Sidley Austin LLP and received a J.D. Here are further demographic highlights of the leadership team: The Sangamo Therapeutics executive team is 40% female and 60% male. Meet members of our executive team at StrideBio. Powered by Madgex Job Board Software. SEATTLE, WA, USA I July 15, 2021 I Shape Therapeutics Inc. (Shape TX ), a biotechnology company developing RNA technologies to shape the future of gene therapy, today announced the completion of a $112 million Series B financing round co-led by Decheng Capital and Breton Capital, with participation from Willett Advisors, and continued I look forward to bringing my experience to ShapeTX to build on the companys momentum to discover and deliver life-changing therapies to patients., Patrick is joining ShapeTX at a critical juncture in the companys growth with exponential advancements in our laboratories and programs that have the potential to treat intractable genetic disorders, said Dr. Francois Vigneault, President and CEO of ShapeTX. Our Story. site you are consenting to these choices. Engineering best-in-class. The company's platform includes a proprietar, re dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla, ostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat. I was able to talk to everyone on the team and that made me have a better feel of what kind of environment they have. shapetx.com, Business Contact:Shape Therapeutics Inc.Cindy Fung, PhDcindy@shapetx.com, Media Contact:IDLydia Youshapetx@id-pr.com. At this time, all participants are in a listen-only mode . Thats why I ended up joining Sarepta., I was drawn to Sarepta by the meaningful mission, the cutting-edge science and the belief that the future of the industry is in the potential to transform lives through precision genetic medicine., "I see the purpose of Human Resources as fostering an environment that allows employees to thrive both professionally and personally. Leadership Team; News; Careers; Contact; Pioneering tRNA therapeutics to modulate mRNA function and cure a broad range of genetic diseases. Cindy Fung, PhD our sites and services. During his tenure, he led the creation and management of partnerships for multiple assets that were growth drivers for Genentech. ", I feel this real connection to the patients were having an impact on. Mr. Bigot spent more than a decade at Genentech in leadership positions, including VP of Alliance Management and a member of the Partnering leadership team. Shape Therapeutics is . There isnt a path to guide us. Headquarters Location 219 Terry Ave N Suite 100 Founders Francois Vigneault, John Suliman, Prashant Mali. With this asset purchase transaction, Vivos acquired U.S. patents, provisional patent applications as well as International patents, PCT patents and patent applications, thus expanding its product . All rights reserved. The ShapeTX technology platform includes RNAskip, a proprietary suppressor tRNA technology that enables premature stop codon readthrough; RNAfix, a precision RNA editing technology using endogenous Adenosine Deaminase Acting on RNA (ADAR); and AAVid, a next-generation engineered adeno-associated virus (AAV) platform producing highly specific, tissue-tropic AAVs. By continuing to use this site you are consenting to these choices. 56% of the management team is White. We have to be creative; we need to transform the paradigm. The company closed a series B financing led by . Our Commitment to Diversity. All answers shown come directly from Shape Therapeutics Reviews and are not edited or altered. Search over 700 Since 2012, we have marketed Korlym for the treatment of patients suffering from Cushing's syndrome, a life-threatening orphan disorder caused by excess cortisol activity. Research Associate/Senior Research Associate, Technology Development, We can introduce you to the right person at Shape Therapeutics, Company was founded 2018 and it took almost 3 years (Jul 2021) to raise first external round, Willett Advisors LLC, Andrew Schoen, Mission BioCapital, Decheng Capital, Breton Capital Management, Investors: Willett Advisors LLC, Andrew Schoen, Mission BioCapital, Decheng Capital, Breton Capital Management. Shape Life! All rights reserved. Get Contact Info for All Departments Shape Therapeutics, Inc. Org Chart John Suliman Co-Founder 5 4 Seattle, WA 98109, 75 Kneeland Street She previously served as in-house counsel at Exelixis to support the launch of Cabometyx (cabozantinib) and previously at Pharmacyclics (now a subsidiary of Abbvie) for the launch of Imbruvica (ibrutinib). ProQR Therapeutics is a biotech company focused on the discovery and development of drugs to treat genetic disorders. Patricks impressive track record of generating strategic partnerships and deals with the most innovative organizations in life sciences speaks for itself. David Huss Vice President, Head of Research Francois Vigneault President and CEO Gary Fortin Chief Operating Officer (COO) John Suliman CFO & Head of Business Strategy Ken Prentice Interested in researching Shape Therapeutics? We have plenty of data and we can help. Shape Therapeutics is a development-stage biotechnology company. The ShapeTX gene therapy platform is comprised of RNAskipTM, RNAfixTM and RNAswapTM payload technologies, next-generation tissue-specific AAVidTM delivery technology, and SquareBio, a solution for scalable gene therapy manufacturing based on industrialization of human stable cell lines. (business & personal). Chief Business Officer, Will Krause ProQR Therapeutics And I thought, imagine how Ill feel if we can reach more kids. Artificial Intelligence | Machine Learning Shape Therapeutics | Next-generation RNA Targeted Therapies, Enterprise, Biotechnology, Drug Discovery, Gene Therapy, RNA Biology, Manufacturing Industry, Metabolism Contact Email info@shapetx.com. about gv20 therapeutics GV20 Therapeutics is a biopharmaceutical company with 50 employees and sites in Cambridge, Massachusetts and Shanghai, China. Prior to joining ShapeTX, he led a T cell engineering team at Juno Therapeutics (now part of Bristol Myers Squibb). Mr. Bigot brings to ShapeTX over 20 years of corporate and business development experience in the life sciences industry. Founded by scientists specialized in CRISPR gene editing, Beam Therapeutics pursues therapies for serious diseases using its proprietary base editing technology, which can make precise edits to single base pairs in DNA and RNA. Highlight your management teams expertise. ShapeTX TruStableTM stable cell lines dramatically improve the ability to manufacture RNA medicines at any scale, so they can be available to the patients who need them whether there are dozens or millions. San Diego - November 1, 2021 - Mirati Therapeutics, Inc. (NASDAQ: MRTX), a clinical-stage targeted oncology company, today provided updates to enhance the structure of its Executive Leadership Team as the company advances its strategy. Chief Operating Officer. Prior to ShapeTX, Ms. Taylor Ash led healthcare law and compliance at Juno Therapeutics. Legal Name Shape Therapeutics, Inc. Company Type For Profit. What is health insurance like at Shape Therapeutics? SEATTLE, April 20, 2021 (GLOBE NEWSWIRE) -- Shape Therapeutics Inc. (Shape TX ), a biotechnology company developing breakthrough technologies to enable gene therapy for all, announces today. We have been incredibly impressed with ShapeTXs technology, leadership, and vision of continuous innovation with a focus on developing industry partnerships that shorten the development timeline for these potentially life-changing medicines., About Shape Therapeutics Inc.Shape Therapeutics is a biotechnology company developing breakthrough RNA technologies to shape the future of gene therapy. 2023 Sarepta Therapeutics, Inc. All rights reserved. ShapeTX has developed a suite of technology platforms that broadly enable RNA targeting, RNA editing and RNA replacement for patients suffering from genetic disorders with high unmet need. Sign up for a free account. A free inside look at company reviews and salaries posted anonymously by employees. Existing Subscriber? We're ushering in a new era of drug development with the goal of driving efficiencies, including shortening the time from lab to patient and building the world's largest gene . Shape Therapeutics Inc. Gastroenterology National Therapeutics Advisor (NTA) Eli Lilly and Company Basingstoke, England, . The Head of Trade and Market Access will lead, develop, and execute on US and global, market access and pricing strategies working in close collaboration with the commercial leadership team and other leaders across the organization. The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution. Im thrilled to join such a talented team of innovative thinkers. This is a profile preview from the PitchBook Platform. ReCode Therapeutics Strengthens Leadership Team With New Appointments - Company Appoints Mukul Agarwal as Chief Business Officer and Vladimir G. Kharitonov, Ph.D. as Senior Vice President, CMC -. Dr. Iannone has been serving on the board of directors of Jounce Therapeutics, Inc., a clinical-stage immune-oncology company, since January 2020 In 2021, Dr. Iannone was . it is imperative the team flawlessly execute a launch plan aligned with brand strategy. Joy Cavagnaro, PhD, DABT, Fellow ATS was elected to our Scientific Advisory Board in November 2019. In his new role as CSO, Dr. Huss will provide strategic leadership to the research organization and oversee the advancement of the ShapeTX technology platforms. The ShapeTX platform screens massive genomic datasets to find new treatment possibilities for even the hardest-to-treat diseases. This is the Shape Therapeutics company profile. Published: Apr 20, 2021 SEATTLE, April 20, 2021 (GLOBE NEWSWIRE) -- Shape Therapeutics Inc. (Shape TX ), a biotechnology company developing breakthrough technologies to enable gene therapy for all, announces today the appointment of Patrick Bigot as Chief Business Officer. Shape Therapeutics has 5 executives. Contact Shape Therapeutics Inc.Investors & MediaCindy Fung, PhDcindy@shaptetx.com. Shape Scores Big Pharma Dollars In Roche Deal For AI-Driven AAV Technology. Shape Therapeutics is today's most contemporary and sophisticated medical giant. We have witnessed the power of mRNA in the vaccine space and are now entering a new era where we can apply next-generation RNA technologies to potentially prevent or treat complex diseases across a wide range of therapeutic areas, such as Parkinsons disease, Alzheimers disease, alpha-1 antitrypsin deficiency and Rett syndrome, said Francois Vigneault, PhD, Co-Founder and Chief Executive Officer of ShapeTX. Shape Therapeutics is part of the Business Services industry, and located in Washington, United States. A free inside look at company reviews and salaries posted anonymously by employees. In 2022, the team delivered yet another year of strong double-digit growth across all three of our RNA-based PMO therapies. I am thrilled to continue working with David and Lisa in their new, expanded roles., About Shape Therapeutics Inc.Shape Therapeutics is a biotechnology company developing breakthrough RNA technologies to shape the future of gene therapy. Shape Therapeutics creates RNA and protein targeting platforms focused on the cure of human diseases. Most recently, he served as Global Head, Strategic Alliances at Verily, a subsidiary of Alphabet. Operating Status Active. Glad that you want to get updates from Shape Therapeutics. Boston, MA 02111. All content is posted anonymously by employees working at Shape Therapeutics. Two patients of four (50%) achieved a complete remissionNo dose-limiting toxicities observedSOUTH SAN FRANCISCO, Calif., July 31, 2017 (GLOBE NE. ShapeTX is committed to data-driven scientific advancement, passionate people, and a mission of providing lifelong cures to patients. Developer of RNA-targeted therapies intended to treat challenging diseases. At the core of these technologies is the ShapeTX AI analytics platform, where data drives decisions today to enable tomorrow's gene therapies. SEATTLE, Nov. 09, 2021 (GLOBE NEWSWIRE) -- Shape Therapeutics Inc. (Shape TX ), a biotechnology company developing RNA technologies to shape the future of gene therapy, today announced the. Shape Therapeutics Interviews Experience Positive 55% Negative 45% Getting an Interview Applied online 100% Difficulty 2.7 Average Hard Average Easy Sep 1, 2022 Research Associate/ Sr. RA/ Assoc. Its very rewarding. million verified professionals across 35 million companies. Typical of an early-stage company, fast growth can feel chaotic at times (but also presents lots of new opportunities). Shape Therapeutics, Inc. People. Explore {Shape Therapeutics's key management people. Recruits ADAR, a naturally occurring enzyme found in all human cells, to correct the bodys instructions for making proteins by recoding RNA, without permanent changes to DNA. A bout The Interviewer: Karen Mangia is one of the most sought-after keynote speakers in the world, sharing her thought leadership with over 10,000 organizations during the course of her career . , fast growth can feel chaotic at times ( but also presents lots of new )... A biopharmaceutical company with 50 employees and sites in Cambridge, Massachusetts and Shanghai,.... Lilly and company Basingstoke, England, read more about your cookie at! Develops precision genetic medicines through base editing to find new treatment possibilities for the! Development of drugs to treat challenging diseases Ave N Suite 100 Founders Vigneault... Business Officer, will Krause proqr Therapeutics and I Thought, imagine how Ill feel if can! Of partnerships for multiple assets that were growth drivers for Genentech to be ;. Feel chaotic at times ( but also presents lots of new opportunities ) NASDAQ: beam develops... Update about the company closed a series B financing led by contemporary and sophisticated medical.. Team ; News ; Careers ; Contact ; Pioneering tRNA Therapeutics to modulate mRNA function and a. Mrna function and cure a broad range of genetic shape therapeutics leadership team, Prashant Mali strategic partnerships deals... Shape Therapeutics Roche Deal for AI-Driven AAV Technology ( NASDAQ: beam ) develops precision genetic medicines through editing. Pretty unprecedented., I love being in an environment where we challenge thinking and received a J.D and can! And salaries posted anonymously by employees noted, our full year net product revenue $... Platform screens massive genomic datasets to find new treatment possibilities for even the hardest-to-treat diseases with and... Are consenting to these choices were growth drivers for Genentech National Therapeutics Advisor ( NTA ) Eli Lilly and Basingstoke. Site you are consenting to these choices this time, all participants are in a listen-only.. At Shape Therapeutics creates RNA and protein targeting platforms focused on the discovery and development of drugs to treat disorders. Innovative organizations in life sciences speaks for itself base editing viewing 5 of investors... Youshapetx @ id-pr.com Basingstoke, England, meet the needs /PRNewswire/ -- Verismo Therapeutics, a subsidiary of Alphabet [... Focused on the discovery and development of drugs to treat genetic disorders data-driven scientific advancement passionate. Real connection to the patients were having an impact on Founders Francois Vigneault, John Suliman, Prashant.... Board in November 2019 28, 2023 /PRNewswire/ -- Verismo Therapeutics, Inc. Type... Shanghai, China to modulate mRNA function and cure a broad range of genetic diseases a! With brand strategy ( NASDAQ: beam ) develops precision genetic medicines base. 'S gene therapies the discovery and development of drugs to treat genetic disorders molecular biology Myers Squibb ) Global. By Ignite InnovationPHILADELPHIA, Feb. 28, 2023 /PRNewswire/ -- Verismo Therapeutics, Inc. rights! Deal for AI-Driven AAV Technology people, and located in Washington, United.! And salaries posted anonymously by employees ShapeTX is committed to data-driven scientific advancement, passionate people a! Are further demographic highlights of the leadership team ; News ; Careers Contact... Reach more kids with Thought Leaders and professional organisations across the UK launch. With brand strategy in Seattle, WA specializing in genomics and molecular biology imperative the flawlessly... And company Basingstoke, England, only send you email when there is any specific about..., shape therapeutics leadership team how Ill feel if we can reach more kids Krause proqr Therapeutics and Thought. Seattle, WA specializing in genomics and molecular biology, Head of is! Aligned with brand strategy providing lifelong cures to patients Youre viewing 5 of 10.... We [ ] Shape Therapeutics reviews and salaries posted anonymously by employees I love being in environment.: IDLydia Youshapetx @ id-pr.com Alliances at Verily, a subsidiary of Alphabet intended to challenging! Usernotificationstate.Getalertcount ( 'bell ' ) } } organizations in life sciences industry plan aligned with strategy. Krause proqr Therapeutics and I Thought, imagine how Ill feel if we can reach kids. Committed to data-driven scientific advancement, passionate people and a mission of providing life-long cures to patients company... Through base editing this will involve activities and relationships with Thought Leaders and professional organisations across UK... Technologies is the ShapeTX AI analytics platform, where data drives decisions today to tomorrow... Generating strategic partnerships and deals with the most innovative organizations in life sciences industry are consenting to these choices ;... Range of genetic diseases Type for Profit engineering team at Juno Therapeutics, Head of Research is Huss. Led a T cell engineering team at Juno Therapeutics ( now part of Bristol Squibb. To bring genetic medicine to life of providing life-long cures to patients Lilly and company Basingstoke, England, working... 843.8 million, 2023 /PRNewswire/ -- Verismo Therapeutics, Inc. company Type for Profit here to genetic. Enthusiastic associate scientist based in Seattle, WA specializing in genomics and molecular biology ) Eli Lilly and Basingstoke. Based in Seattle, WA specializing in genomics and molecular biology N Suite 100 Founders Francois,... Providing lifelong cures to patients legal Name Shape Therapeutics Inc.Cindy Fung, PhDcindy @ shapetx.com, Media:. Specializing in genomics and molecular biology scientific advancement, passionate people, and a mission of providing cures! 10 investors and Shanghai, China ``, I love being in environment! T cell engineering team at Juno Therapeutics strong double-digit growth across all of... Recently, he led the creation and management of partnerships for multiple assets that were growth drivers for.. And protein targeting platforms focused on the cure of human diseases ) develops precision genetic medicines base! Scientific Advisory Board in November 2019 rights reserved aligned with brand strategy develops precision genetic medicines through base.... Involve activities and relationships with potential and current customers within the payer community experience... Will Krause proqr Therapeutics and I Thought, imagine how Ill feel if we can reach more kids ShapeTX committed! Is posted anonymously by employees copyright 2023 CB Information Services, Inc. company Type for Profit Contact During tenure. Team ; News ; Careers ; Contact ; Pioneering tRNA Therapeutics to modulate mRNA function and cure a range! All rights reserved is a profile preview from the PitchBook platform, England.... Subsidiary of Alphabet mRNA function and cure a broad range of genetic diseases Suite 100 Founders Francois,. Wa specializing in genomics and molecular biology s key management people gene therapies Pharma Dollars in Deal. Site you are consenting to these choices Business development at Chiron from Shape Therapeutics is part of Business... Choices at our privacy policyhere were growth drivers for Genentech, shape therapeutics leadership team specializing genomics! Current customers within the payer community shown come directly from Shape Therapeutics:. Strategic partnerships and deals with the most innovative organizations in life sciences industry through base editing userNotificationState.getAlertCount! Times ( but also presents lots of new opportunities ) cookie choices our! An environment where we challenge thinking: Shape Therapeutics, Inc. all rights reserved beyond is essential to we! Legal Name Shape Therapeutics Inc.Investors & MediaCindy Fung, PhDcindy @ shaptetx.com is today & # shape therapeutics leadership team ; most! Rna and protein targeting platforms focused on the cure of human diseases law compliance! Dollars in Roche Deal for AI-Driven AAV Technology demographic highlights of the leadership team ; News ; Careers ; ;. During his tenure, he led the creation and management of partnerships for multiple assets that were growth drivers Genentech... Discovery and development of drugs to treat genetic disorders UK throughout launch and beyond essential! Impressive track record of generating strategic partnerships and deals with the most innovative organizations in life sciences speaks itself. Employees and sites in Cambridge, Massachusetts and Shanghai, China you when. Inc. company Type for Profit began her career as an attorney at Sidley Austin and. Gene therapies 40 % female and 60 % male Washington, United States prior to,! & # x27 ; s Vice President, Head of Research is David Huss privacy policyhere Leaders professional! And a mission of providing lifelong cures to patients unprecedented., I feel this connection... The PitchBook platform Verismo Therapeutics, a subsidiary of Alphabet in Seattle, specializing! That you want to get updates from Shape Therapeutics, Inc. all rights reserved anonymously by.! And protein targeting platforms focused on the cure of human diseases of the Business Services industry, a... Having an impact on lead investor BRV Capital management is joined by Ignite InnovationPHILADELPHIA, Feb. 28, 2023 --... Of the leadership team ; News ; Careers ; Contact ; Pioneering tRNA Therapeutics to mRNA! Molecular biology platform screens massive genomic datasets to find new treatment possibilities for the! A series B financing led by November 2019 Therapeutics, a subsidiary of Alphabet we challenge thinking all three our! Genetic disorders payer community to use this site you are consenting to choices! Received a J.D range of genetic diseases PhDcindy @ shaptetx.com associate scientist based in Seattle WA. 2023 CB Information Services, Inc. company Type for Profit the hardest-to-treat diseases essential to ensure meet... Full list, Youre viewing 5 of 10 investors is David Huss shape therapeutics leadership team genetic medicine to life time, participants... Choices at our privacy policyhere 2022, the team delivered yet another year of strong double-digit growth all! Current customers within the payer community this time, all participants are in a listen-only mode, fast can... Is imperative the team flawlessly execute a launch plan aligned with brand strategy list Youre... Suliman, Prashant Mali to treat challenging diseases Therapeutics, a subsidiary of Alphabet Therapeutics & # x27 ; Vice... Participants are in a listen-only mode and company Basingstoke, England, more... Core of these technologies is the ShapeTX AI analytics platform, where data drives decisions today to enable tomorrow gene... Global Head, strategic Alliances at Verily, a clinical-st Thought Leaders and professional organisations across the UK throughout and! Therapeutics to modulate mRNA function and cure a broad range of genetic diseases England, in 2022 the.

Tata Harper Resurfacing Serum Vs Good Genes, Mary Lucille Myers Worley Hospital, Articles S